Compare Meta Platforms Inc (META) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs BIO-TECHNE Corp — how do they compare? Meta Platforms Inc trades at $605.78 (market cap $1.52T), while BIO-TECHNE Corp trades at $72.07 (market cap $11.24B). The key difference: Meta Platforms Inc is far larger — about 135.2× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays the higher dividend (0.44%). Which is the better fit depends on your goals.
| META | TECH | |
|---|---|---|
Market Cap | $1.52T | $11.24B |
Volume | 24,093,972 | — |
Sector | Media | Health |
52-Week High | $790.00 | $72.29 |
52-Week Low | $525.72 | $43.31 |
Enterprise Value | $1.54T | $11.32B |
Dividend Yield | 0.35% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Meta Platforms trades at $606.00, up 2.35% with strong earnings momentum despite a recent Q2 2026 miss. The stock shows bearish technical signals but maintains robust fundamentals with 81.75% gross margins and 29.84% net income margin. Recent AI developments including Muse Spark launch and a $21 billion CoreWeave deal highlight growth initiatives, though legal challenges persist with Massachusetts' youth addiction lawsuit proceeding.
Outlook remains positive with 79% analyst buy ratings and $761.95 consensus target offering 26% upside. Key risks include elevated capex for AI investments and regulatory scrutiny, but strong cash flow generation and market positioning support long-term growth potential for investors seeking tech exposure.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
